984 results on '"MORISCO, FILOMENA"'
Search Results
52. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study
53. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma
54. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
55. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
56. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma
57. Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology
58. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort
59. Visceral Obesity and Cytokeratin-18 Antigens as Early Biomarkers of Liver Damage
60. COVID-19 and Fatty Liver Disorders
61. Ribociclib in newly diagnosed hepatitis B infection: A case report
62. Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
63. Implementation of anti-HDV reflex testing among HBsAg-positive in a tertiary center in South Italy
64. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
65. Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey
66. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)
67. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference
68. AISF position paper on liver disease and pregnancy
69. Predicting de‐novoportal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort
70. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
71. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
72. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma
73. Anti‐HDV reflex testing in HBsAg‐positive subjects: An efficacious strategy to identify HDV infection.
74. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination
75. Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
76. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study
77. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
78. Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy
79. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma
80. The unhealthy lifestyle in primary biliary cholangitis: An enemy to fight
81. An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C
82. Application of PTR-TOF-MS to investigate metabolites in exhaled breath of patients affected by coeliac disease under gluten free diet
83. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma
84. Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease
85. Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin
86. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy
87. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison
88. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
89. Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
90. Vitamin D levels and chronic hepatitis C
91. Garlic extract attenuating rat liver fibrosis by inhibiting TGF-β1
92. Hepatitis C Virus Clearance in Older Adults
93. Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross‐sectional multicenter study
94. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma
95. Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades
96. The evolutionary scenario of hepatocellular carcinoma in Italy: an update
97. Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma.
98. Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
99. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
100. Type 2 diabetes combined with portal vein tumor thrombosis worsens prognosis in patients with hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.